Fibrinogen Degradation Products and D-Dimers in Patients with Breast Carcinoma
Background: Many patients with cancer are complicated by disseminated intravascular coagulation. This study was aimed to determine the level of Fibrinogen Degradation Products and D-Dimers at various stages in patients suffering from breast carcinoma. Material and methods: This was a cross-section...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Gomal Medical College, D.I.Khan, Pakistan
2007-06-01
|
Series: | Gomal Journal of Medical Sciences |
Online Access: | http://gjms.com.pk/ojs24/index.php/gjms/article/view/95 |
id |
doaj-055da85f13554662bd2cd83dfd49a385 |
---|---|
record_format |
Article |
spelling |
doaj-055da85f13554662bd2cd83dfd49a3852020-11-25T01:43:47ZengGomal Medical College, D.I.Khan, PakistanGomal Journal of Medical Sciences1819-79731997-20672007-06-015195Fibrinogen Degradation Products and D-Dimers in Patients with Breast CarcinomaMalik Zeb KhanMuhammad Shoaib KhanFazle RaziqAziz Marjan KhattakBackground: Many patients with cancer are complicated by disseminated intravascular coagulation. This study was aimed to determine the level of Fibrinogen Degradation Products and D-Dimers at various stages in patients suffering from breast carcinoma. Material and methods: This was a cross-sectional study conducted in the Department of Pathology, Postgraduate Medical Institute, Lahore, Pakistan, from June 2003 to June 2004. Sampling method was by convenience. Two groups were taken; Group-1 including 50 patients with breast carcinoma and Group-2 comprising of 25 healthy controls. Fibrinogen Degradation Products and D-Dimer levels were estimated in the blood and the results compared. Results: Out of 50 patients, 28 (56%) had Fibrinogen Degradation Products >40 μg/ml; 13 (26%) in stageIII and 15 (30%) in stage-IV. 15 (30%) patients had levels between 5-40μg/ml; 8 (16%) in stage-II and 7 (14%) in stage-III. Only 7 (14%) had levelshttp://gjms.com.pk/ojs24/index.php/gjms/article/view/95 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Malik Zeb Khan Muhammad Shoaib Khan Fazle Raziq Aziz Marjan Khattak |
spellingShingle |
Malik Zeb Khan Muhammad Shoaib Khan Fazle Raziq Aziz Marjan Khattak Fibrinogen Degradation Products and D-Dimers in Patients with Breast Carcinoma Gomal Journal of Medical Sciences |
author_facet |
Malik Zeb Khan Muhammad Shoaib Khan Fazle Raziq Aziz Marjan Khattak |
author_sort |
Malik Zeb Khan |
title |
Fibrinogen Degradation Products and D-Dimers in Patients with Breast Carcinoma |
title_short |
Fibrinogen Degradation Products and D-Dimers in Patients with Breast Carcinoma |
title_full |
Fibrinogen Degradation Products and D-Dimers in Patients with Breast Carcinoma |
title_fullStr |
Fibrinogen Degradation Products and D-Dimers in Patients with Breast Carcinoma |
title_full_unstemmed |
Fibrinogen Degradation Products and D-Dimers in Patients with Breast Carcinoma |
title_sort |
fibrinogen degradation products and d-dimers in patients with breast carcinoma |
publisher |
Gomal Medical College, D.I.Khan, Pakistan |
series |
Gomal Journal of Medical Sciences |
issn |
1819-7973 1997-2067 |
publishDate |
2007-06-01 |
description |
Background: Many patients with cancer are complicated by disseminated intravascular coagulation. This study was aimed to determine the level of Fibrinogen Degradation Products and D-Dimers at various stages in patients suffering from breast carcinoma.
Material and methods: This was a cross-sectional study conducted in the Department of Pathology, Postgraduate Medical Institute, Lahore, Pakistan, from June 2003 to June 2004. Sampling method was by convenience. Two groups were taken; Group-1 including 50 patients with breast carcinoma and Group-2 comprising of 25 healthy controls. Fibrinogen Degradation Products and D-Dimer levels were estimated in the blood and the results compared.
Results: Out of 50 patients, 28 (56%) had Fibrinogen Degradation Products >40 μg/ml; 13 (26%) in stageIII and 15 (30%) in stage-IV. 15 (30%) patients had levels between 5-40μg/ml; 8 (16%) in stage-II and 7 (14%) in stage-III. Only 7 (14%) had levels |
url |
http://gjms.com.pk/ojs24/index.php/gjms/article/view/95 |
work_keys_str_mv |
AT malikzebkhan fibrinogendegradationproductsandddimersinpatientswithbreastcarcinoma AT muhammadshoaibkhan fibrinogendegradationproductsandddimersinpatientswithbreastcarcinoma AT fazleraziq fibrinogendegradationproductsandddimersinpatientswithbreastcarcinoma AT azizmarjankhattak fibrinogendegradationproductsandddimersinpatientswithbreastcarcinoma |
_version_ |
1725031484397453312 |